Menu
Recruiting NCT06227611

Evaluation of Different Perimetric Grids to Detect Central Visual Field Defect in Glaucoma Patients with Reduce Ganglion Cell Layer Thickness Measured by Spectral Domain OCT.

— Observational Glaucoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Glaucoma. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Italy
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The aim of the study is to evaluate the agreement between three different grids in detecting central visual field defect in early glaucoma patients with reduced ganglion cell layer thickness.

Primary outcome measures

  • the agreement between 10-2 HFA and 24-2c HFA in detecting central visual field defect [Time frame: 12 month]
Secondary outcome measures (1)
  • the agreement between 24-2c HFA and G1 Octopus in detecting central visual field defect [Time frame: 12 month]

Eligibility criteria

Inclusion criteria

  • glaucoma patients with glaucomatous optic nerve head defect and reduced ganglion cell layer thickness

Exclusion criteria

  • age<18 years
  • unable to read, understand and sign the written informed consent
  • unable to perform visual field test
  • advanced glaucoma with C/D>0.7
  • other causes of optic neuropathies
  • retinal or macular diseases
  • lens or corneal opacities
  • spherical refractive defect >± 6D
  • cylindric refractive defect >± 3D

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Italy · 2 centers
  • IRCCS-Fondazione GB Bietti — Rome
  • University of Rome Tor Vergata — Rome

Identifiers

NCT: NCT06227611 · GLC04-20

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗